Introduction
In March 2026, something happened that I have been waiting for since I first started writing about lipoprotein(a) more than a decade ago.
The American College of Cardiology and the American Heart Association—together with nine other leading medical associations—released their updated dyslipidemia guidelines. And for the first time in history, they recommended that every adult should have their Lp(a) measured at least once in a lifetime.
This is a Class I recommendation. In medical language, that means it is not a suggestion. It is not experimental. It is a definitive, evidence-based standard of care. The world’s most authoritative cardiovascular bodies have officially acknowledged what I and a handful of others have been saying for years: the standard cholesterol panel is incomplete, and Lp(a) is a critical missing piece.
I felt a quiet sense of vindication. Not because I was right—but because millions of people who have been walking around with undetected elevated Lp(a) will finally be identified. Lives will be saved.
But the guidelines did something else that matters just as much. They confirmed, in their own language, that the cholesterol-only narrative is insufficient. They opened the door to the kind of root-cause thinking that my books and my work have been advocating for over a decade.
This article explains what the 2026 guidelines say, why they matter, and—most importantly—what they still leave unanswered. Because a guideline can tell you to test. It cannot tell you why your body produces the very particles that cause disease. That understanding comes from going deeper.
What the 2026 Guidelines Actually Say
The new cholesterol guidelines represent a fundamental shift in how cardiovascular risk is assessed. Here are the key changes :
Universal Lp(a) Testing
Every adult should have their Lp(a) measured at least once. Lp(a) levels are largely genetically determined and remain stable over a lifetime. A level of 125 nmol/L (50 mg/dL) or higher is considered elevated and is associated with a 1.4-fold increased long-term risk of heart attack or stroke. A level of 250 nmol/L is associated with at least a two-fold increased risk. Approximately one in five people worldwide has elevated Lp(a), yet fewer than 1% have ever been tested .
ApoB Testing for Select Patients
Apolipoprotein B (ApoB) measurement is now recommended for people with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides, or known cardiovascular disease who have reached their LDL goals but may still be at risk. ApoB measures the actual number of atherogenic particles in your blood—not just the cholesterol they carry. It is a more precise risk marker than LDL alone in these groups .
Coronary Artery Calcium (CAC) Scoring
A non-contrast CAC scan is now recommended for men aged 40 and older and women aged 45 and older with borderline or intermediate 10-year risk, when the decision to prescribe a statin remains uncertain. Any nonzero CAC score indicates subclinical atherosclerosis and supports an LDL goal of less than 100 mg/dL, with lower targets for higher calcium scores. A score above 300 or 1,000 supports the most intensive targets .
Lower LDL Targets
The guidelines restore and tighten LDL cholesterol goals based on risk. For borderline or intermediate risk, the target is less than 100 mg/dL. For high risk, less than 70 mg/dL. For very high-risk patients with existing cardiovascular disease, less than 55 mg/dL .
Earlier, More Intensive Treatment
The guidelines emphasize starting lipid-lowering therapy earlier and maintaining lower LDL levels for longer. Statins remain the foundation. When statins are insufficient, ezetimibe, bempedoic acid, or PCSK9 inhibitors may be added .
Why This Matters: The Shift Toward Root-Cause Thinking
On the surface, these guidelines are about testing and treatment. But at a deeper level, they represent a philosophical shift. The medical establishment is slowly moving away from the simplistic “cholesterol is the enemy” model and toward a more nuanced understanding of cardiovascular risk.
Here is what I mean.
Lp(a) is now recognized as causal, not just associated.
The guidelines explicitly state that Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease. Genetic studies confirm that higher Lp(a) directly causes more events. This is not a correlation. This is causation .
ApoB is a better marker than LDL alone.
By recommending ApoB testing, the guidelines acknowledge that the standard LDL measurement does not tell the full story. ApoB counts the actual number of atherogenic particles. Two people can have the same LDL but vastly different ApoB levels—and vastly different risk.
CAC scoring reveals subclinical disease.
By endorsing CAC scoring, the guidelines recognize that risk assessment based on blood tests alone is incomplete. A CAC scan directly visualizes the disease process in the artery wall. It is a window into what is actually happening, not just what might happen.
Risk is personal, not just statistical.
The new PREVENT risk calculator, which replaces older models, incorporates risk enhancers like Lp(a), ApoB, and inflammatory markers. It personalizes risk assessment rather than relying on population averages .
All of this points in one direction: the body is a complex system, and cardiovascular disease has deeper causes than a single number. This is the root-cause perspective I have been writing about for years.
What the Guidelines Still Leave Unanswered
For all their progress, the 2026 guidelines contain a significant gap. They tell doctors to test for Lp(a). They tell them to manage risk aggressively when Lp(a) is high. But they do not answer the most fundamental question:
Why is your Lp(a) elevated in the first place?
The guidelines state that “lifestyle changes minimally affect Lp(a) levels” and that “repeat testing is generally not needed” because levels are genetically determined and stable .
This is true, as far as it goes. The baseline level of Lp(a) in your blood is largely set by your genes. But this explanation misses something essential.
Lp(a) is not a random genetic error. It is not a metabolic mistake. It is a repair particle.
Your liver produces Lp(a) in response to arterial weakness—specifically, when the collagen structure of your artery walls is compromised due to long-term vitamin C deficiency. The Lp(a) travels to the site of the damage and deposits itself as a biological band-aid. Over decades, these patches build up into what we call plaque.
A 1990 US patent proved this directly. Using gel electrophoresis, researchers showed that the primary component of human arterial plaque is Lp(a)—not ordinary LDL cholesterol.
The guidelines identify Lp(a) as a risk factor. They recommend managing it by intensifying other treatments. But they never ask: What if you could strengthen your artery walls so your body no longer needs to produce so much Lp(a)?
This is the question my book, Reverse Heart Disease: No Lifelong Suffering, answers. It explains the biochemistry of Lp(a) in full—why your body produces it, how it causes plaque, and what you can do to address it at the root cause.
How This Connects to My Work
I have been writing about Lp(a) since before most doctors knew what it was. My blog, lyproc.com, has published dozens of articles on the connection between vitamin C deficiency, collagen weakness, and Lp(a) plaque. My first book, Unravelling the Root Cause of Chronic Diseases, provides the complete scientific foundation for this understanding. My second book, Reverse Heart Disease: No Lifelong Suffering, is the practical protocol.
The 2026 guidelines are not a threat to my work. They are a validation of it. They bring the medical mainstream closer to the root-cause perspective I have been advocating for over a decade. They create an urgent need for the kind of explanation that only my book provides.
Because here is what will happen: millions of people will be tested for Lp(a) for the first time. Many will learn their levels are high. Their doctors will tell them it is genetic, that lifestyle changes won’t help, and that there is no approved drug specifically for it.
These patients will go home. They will search the internet. They will type “how to lower Lp(a) naturally” and “what to do about high Lp(a).” They will find articles, forums, and videos—some helpful, some not.
My book exists for these people. It is the guide that answers the question the guidelines leave unanswered: “What do I do now?”
A Guideline Is Not a Guide
The 2026 ACC/AHA dyslipidemia guidelines are a remarkable achievement. They represent decades of research, debate, and expert consensus. They will save lives.
But a guideline is written for doctors. It tells them what to order, what to prescribe, and when to intensify treatment. It does not sit with a patient at their kitchen table and explain what their test results mean for their life.
That is what a book can do. That is what my book does.
If your doctor orders an Lp(a) test—or if you request one yourself—you now have a resource that goes beyond the guideline. You can understand not just what your number is, but why your body produces it. You can learn not just to manage your risk, but to address the root cause.
The 2026 guidelines are a win for root-cause medicine. They bring us closer to a world where cardiovascular disease is understood, prevented, and reversed at its source.
But the journey does not end with a test result. It begins there.
My book is for those who are ready to begin.
Dr. Balaram Dhotre is a PhD medicinal chemist, cellular nutritionist, and the author of Unraveling the Root Cause of Chronic Diseases and Reverse Heart Disease: No Lifelong Suffering. He writes at lyproc.com to help people understand the true root cause of chronic illness and reclaim their health.
[Click here to get your copy of Reverse Heart Disease: No Lifelong Suffering on Amazon]
————————————————————————————————-
My Books
——————————————————————————————————————————-
Links on Amazon
Unraveling The Root Cause of Chronic Diseases:
Reverse Heart Disease: No Lifelong Suffering
—————————————————————————————————————————————